Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma.
Ann Hematol
; 101(2): 335-340, 2022 Feb.
Article
in En
| MEDLINE
| ID: mdl-34668982
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Oligopeptides
/
Lymphoma, T-Cell, Peripheral
/
Neoplasm Recurrence, Local
/
Antineoplastic Agents
Type of study:
Clinical_trials
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Ann Hematol
Journal subject:
HEMATOLOGIA
Year:
2022
Type:
Article
Affiliation country:
United States